| 摘要 |
The present invention provides methods of treating schizophrenia and/or glucoregulatory abnormalities in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compou nd of formula (I) wherein m is 0, 1 or 2; n is 0, 1 or 2; p is 0 or 1; each R i s independently hydrogen, halogen, trifluoromethyl, C1-C6alkyl, C1-C6alkoxy, benzyloxy, hydroxy, nitro or amino; each R1 is independently hydrogen, C1- C6alkyl, C1-C6alkenyl, C1-C6alkanoyl, halogen, cyano, -C(O) C1-C6alkyl, -C1- C6alkyleneCN, -C1-C6alkyleneNR~R~ wherein R~ and R~ are each independently hydrogen or C1-C6alkyl, -C1-C6alkyleneOC(O)C1-C6alkyl, or -CH(OH)R4 wherein R4 is hydrogen or C1-C6alkyl; R2 is hydrogen, C1-C6alkyl optionally substituted with halogen, hydroxy or benzyloxy, C1-C6alkenyl, C1-C6alkynyl, -CO2C1- C6alkyl, or -R5-NR~R~ wherein R5 is C1-C6alkylene, C1-C6alkenylene or C1- C6alkynylene and R~ and R~ are each independently hydrogen, C1-C6alkyl or alternatively the group -NR~R~ as a whole is 1-pyrrolidinyl; and R3 is hydrogen, nitro, amino, halogen, C1-C6alkoxy, hydroxy or C1-C6alkyl or a pharmaceutically acceptable salt thereof.
|
